Sublingual film containing dexmedetomidine (BXCL501)

DRUG3 trials

Conditions

AgitationAgitation Associated With Bipolar DisorderAgitation,PsychomotorBipolar DisorderSchizo Affective DisorderSchizoaffective DisorderSchizophreniaSchizophreniform Disorders

Phase 3

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

CompletedNCT04268303

BioXcel Therapeutics IncAgitation, Schizoaffective Disorder, Schizo Affective Disorder +2

Start: 2020-01-24End: 2020-05-06Updated: 2026-08-11

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

CompletedNCT04276883

BioXcel Therapeutics IncAgitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder

Start: 2020-02-24End: 2020-05-21Updated: 2026-08-11

Phase 4

Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department

WithdrawnNCT05974527

Brigham and Women's HospitalAgitation, Bipolar Disorder, Schizoaffective Disorder +2

Start: 2023-09-01End: 2026-06-30Updated: 2026-01-28

The Journal of Clinical Psychiatry2022-09-2924 citations

Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

Advances in Therapy2022-08-249 citations

Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder

JAMA2022-02-2278 citations

Sublingual film containing dexmedetomidine (BXCL501)

Sponsors

Conditions

Phase 3

Phase 4

Related Papers